Compare BANR & AMPH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | BANR | AMPH |
|---|---|---|
| Founded | 1890 | 1996 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.2B | 1.2B |
| IPO Year | 1995 | 2014 |
| Metric | BANR | AMPH |
|---|---|---|
| Price | $63.34 | $27.02 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 6 | 6 |
| Target Price | ★ $71.20 | $31.00 |
| AVG Volume (30 Days) | 193.4K | ★ 380.6K |
| Earning Date | 01-21-2026 | 11-06-2025 |
| Dividend Yield | ★ 3.12% | N/A |
| EPS Growth | ★ 14.84 | N/A |
| EPS | ★ 5.49 | 2.27 |
| Revenue | $640,027,000.00 | ★ $723,305,000.00 |
| Revenue This Year | $0.96 | $1.35 |
| Revenue Next Year | $7.48 | $5.10 |
| P/E Ratio | ★ $11.67 | $11.81 |
| Revenue Growth | ★ 7.86 | N/A |
| 52 Week Low | $54.01 | $20.39 |
| 52 Week High | $72.58 | $39.01 |
| Indicator | BANR | AMPH |
|---|---|---|
| Relative Strength Index (RSI) | 42.37 | 55.28 |
| Support Level | $66.40 | $26.26 |
| Resistance Level | $67.95 | $27.23 |
| Average True Range (ATR) | 1.22 | 0.76 |
| MACD | -0.42 | 0.06 |
| Stochastic Oscillator | 3.01 | 85.96 |
Banner Corp is a bank holding company. It wholly owns one subsidiary bank, Banner Bank. The Bank's primary business is that of traditional banking institutions, accepting deposits and originating loans in locations surrounding its offices in Washington, Oregon, California, Idaho and Utah. Banner Bank also actively participates in the secondary loan markets, engaging in mortgage banking operations largely through the origination and sale of one to four family residential loans.
Amphastar Pharmaceuticals Inc is a bio-pharmaceutical company focusing on developing, manufacturing, marketing, and selling technically challenging generic and proprietary injectable, inhalation, and intranasal products, as well as insulin active pharmaceutical ingredient, or insulin API products. The company's finished products are used in hospital or urgent care clinical settings and are contracted and distributed through group purchasing organizations and drug wholesalers. The company has one reportable segment pharmaceutical products. Geographically the business presence of the firm is seen in the United States, China and France of which the U.S. accounts for the majority of the revenue.